By the same authors

From the same journal

From the same journal

Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where are we now?

Research output: Contribution to journalArticlepeer-review

Full text download(s)

Published copy (DOI)



Publication details

JournalValue in Health
DateAccepted/In press - 17 Aug 2020
DateE-pub ahead of print - 17 Oct 2020
DatePublished (current) - 1 Dec 2020
Issue number12
Number of pages9
Pages (from-to)1613-1621
Early online date17/10/20
Original languageEnglish


OBJECTIVES: Partitioned survival models (PSMs) are routinely used to inform reimbursement decisions for oncology drugs. We discuss the appropriateness of PSMs compared to the most common alternative, state transition models (STMs).

METHODS: In 2017, we published a National Institute for Health and Care Excellence (NICE) Technical Support Document (TSD 19) describing and critically reviewing PSMs. This article summarizes findings from TSD 19, reviews new evidence comparing PSMs and STMs, and reviews recent NICE appraisals to understand current practice.

RESULTS: PSMs evaluate state membership differently from STMs and do not include a structural link between intermediate clinical endpoints (eg, disease progression) and survival. PSMs directly consider clinical trial endpoints and can be developed without access to individual patient data, but limit the scope for sensitivity analyses to explore clinical uncertainties in the extrapolation period. STMs facilitate these sensitivity analyses but require development of robust survival models for individual health-state transitions. Recent work has shown PSMs and STMs can produce substantively different survival extrapolations and that extrapolations from STMs are heavily influenced by specification of the underlying survival models. Recent NICE appraisals have not generally included both model types, reviewed individual clinical event data, or scrutinized life-years accrued in individual health states.

CONCLUSIONS: The credibility of survival predictions from PSMs and STMs, including life-years accrued in individual health states, should be assessed using trial data on individual clinical events, external data, and expert opinion. STMs should be used alongside PSMs to support assessment of clinical uncertainties in the extrapolation period, such as uncertainty in post-progression survival.

Bibliographical note

This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy.

    Research areas

  • Antineoplastic Agents/economics, Decision Making, Organizational, Humans, Insurance Coverage/economics, Models, Economic, Models, Statistical, Neoplasms/drug therapy, Progression-Free Survival, Survival Analysis

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations